Literature DB >> 8116748

Detection of intraocular antibody production to herpesviruses in acute retinal necrosis syndrome.

J H de Boer1, L Luyendijk, A Rothova, G S Baarsma, P T de Jong, J G Bollemeijer, A J Rademakers, A Van der Lelij, M J Zaal, A Kijlstra.   

Abstract

In order to improve the determination of the causative agent in acute retinal necrosis syndrome, we evaluated the detection of intraocular antibody production to herpesviruses in 28 patients with this disease. Intraocular antibody production was determined by calculation of the Goldmann-Witmer coefficient whereby specific antibody titers in the inflamed eye and circulation are related to the total IgG content in ocular fluid and serum. Specific antibody titers to herpesviruses and Toxoplasma were determined by the indirect immunofluorescence technique. Thirty-five patients with ocular toxoplasmosis, cataract, or proliferative vitreoretinal disorders were tested as controls. By this technique, intraocular antibody production to varicella zoster virus or herpes simplex virus could be established in 16 (57%) of the patients with the typical clinical features of acute retinal necrosis, compared to none of the controls. Of the 33 affected eyes, 21 (64%) had a visual outcome of less than 20/200. We concluded that detection of intraocular antibody production to herpesviruses may be a useful diagnostic tool in establishing the causative agents in acute retinal necrosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8116748     DOI: 10.1016/s0002-9394(14)73077-6

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  23 in total

1.  Are cytokine patterns in aqueous humour useful in distinguishing corneal graft rejection from opacification due to herpetic stromal keratitis?

Authors:  E B van Gelderen; A Van der Lelij; H J Völker-Dieben; R van der Gaag; R Peek; W F Treffers
Journal:  Doc Ophthalmol       Date:  1999       Impact factor: 2.379

2.  Variable R1 region in varicella zoster virus in fulminant type of acute retinal necrosis syndrome.

Authors:  T Abe; M Sato; M Tamai
Journal:  Br J Ophthalmol       Date:  2000-02       Impact factor: 4.638

3.  Detecting herpesvirus DNA in uveitis using the polymerase chain reaction.

Authors:  S Yamamoto; D Pavan-Langston; S Kinoshita; K Nishida; Y Shimomura; Y Tano
Journal:  Br J Ophthalmol       Date:  1996-05       Impact factor: 4.638

4.  Prophylactic vitrectomy for acute retinal necrosis.

Authors:  Tomoka Ishida; Yoshiharu Sugamoto; Sunao Sugita; Manabu Mochizuki
Journal:  Jpn J Ophthalmol       Date:  2009-10-22       Impact factor: 2.447

5.  A comparative study of the polymerase chain reaction and local antibody production in acute retinal necrosis syndrome and cytomegalovirus retinitis.

Authors:  T Abe; K Tsuchida; M Tamai
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-07       Impact factor: 3.117

6.  Polymerase chain reaction analysis of aqueous humour samples in necrotising retinitis.

Authors:  T H C Tran; F Rozenberg; N Cassoux; N A Rao; P LeHoang; B Bodaghi
Journal:  Br J Ophthalmol       Date:  2003-01       Impact factor: 4.638

Review 7.  Analysis of ocular fluids for local antibody production in uveitis.

Authors:  J H de Boer; L Luyendijk; A Rothova; A Kijlstra
Journal:  Br J Ophthalmol       Date:  1995-06       Impact factor: 4.638

8.  Combination systemic and intravitreal antiviral therapy in the management of acute retinal necrosis syndrome (an American Ophthalmological Society thesis).

Authors:  Christina J Flaxel; Steven Yeh; Andreas K Lauer
Journal:  Trans Am Ophthalmol Soc       Date:  2013-09

9.  [Acute retinal necrosis from the virologist's perspective].

Authors:  P Rautenberg; L Grancicova; J Hillenkamp; B Nölle; J B Roider; H Fickenscher
Journal:  Ophthalmologe       Date:  2009-12       Impact factor: 1.059

10.  Antiviral selection in the management of acute retinal necrosis.

Authors:  Patrick M K Tam; Claire Y Hooper; Susan Lightman
Journal:  Clin Ophthalmol       Date:  2010-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.